Please assess the completion status of the following clinical trial:

Trial Title: Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of epithelial ovarian or primary peritoneal cancer~* Measurable disease or evaluable disease with CA125 \>100~* One prior treatment with taxane/platinum based chemotherapy, but patients with recurrent ovarian cancer not receiving platinum-based chemotherapy at time of initial diagnosis will be allowed~* Recurrence after treatment free interval of at least 6 mos from completion of primary chemotherapy~* 19 years of age or older~* Life expectancy of greater than 12 weeks~* Performance status of 0, 1 or 2 (based on GOG Performance Status)~* Normal bone marrow, renal and hepatic function based upon lab tests~* Cardiac ejection fraction within institutional normal range~* Ability to swallow and retain oral medication~* Ability to understand a written informed consent document~Exclusion Criteria:~* Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering study~* Epithelial ovarian tumors of low malignant potential, stromal or germ cell origin~* Non-measurable or non-evaluable disease~* Archived tumor tissue not available for assay~* Patients may not be receiving any other investigational agents or concurrent anticancer therapy, or herbal (alternative) medicines~* Patients with known brain metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent.~* Uncontrolled inter-current illness~* Patients who are pregnant~* HIV-positive patients receiving combination anti-retroviral therapy~* Patients with GI tract disease resulting in an inability to take oral medication

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).